Phase IIIa Clinical Trial of Oral Semaglutide Completed

Novo Nordisk has announced it has completed the second Phase IIIa trial, PIONEER 2, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment of Type 2 diabetes, which utilises Emisphere Technologies’ proprietary Eligen® Technology.

Emisphere is a drug delivery company that utilises its proprietary Eligen® Technology to develop new oral formulations of therapeutic agents. Emisphere partners with global pharmaceutical companies for the development of new orally delivered therapeutics.

More About This Company

Development Update

Novo Nordisk announced the European Commission (EC) has granted marketing authorisation for Rybelsus®, (oral semaglutide),...